Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure

Rhea-AI Summary

Relief Therapeutics has reported positive trial results for its drug aviptadil in treating critical COVID-19 patients with respiratory failure. In a study published in the Journal of Infectious Diseases and Treatment, aviptadil demonstrated a 60-day survival rate of 81%, significantly higher than the 21% survival rate of standard care (P<.0001). Additionally, the treatment showed a 9-fold advantage in recovery from respiratory failure (P<.0001). These results further support Relief's ongoing clinical programs and partnerships aimed at addressing high unmet medical needs.

Positive

• Aviptadil demonstrated an 81% survival rate in a trial, significantly higher than the 21% of standard care.
• The trial showed a 9-fold increased probability of recovery from respiratory failure with aviptadil.
• Publication in a peer-reviewed journal validates the efficacy of aviptadil in critical COVID-19 treatment.

Negative

• None.

GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (" NRx "), has issued a press release announcing that the peer-reviewed Journal of Infectious Diseases and Treatment has published positive trial data from a prospective, open label, administratively controlled trial of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. According to the press release, the study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the Houston Methodist Hospital (P<.0001). The press release also reports that a similar 9-fold advantage was seen in the cumulative probability of recovery from respiratory failure (P<.0001). The related NRx press release can be accessed through the following link .

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100(TM) (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com . Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether RELIEF THERAPEUTICS Holding SA will prevail in its litigation action against NeuroRx over the terms of the Collaboration Agreement, (ii) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (iii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/668307/Relief-Reports-US-Collaboration-Partner-Announces-Journal-of-Infectious-Diseases-and-Treatment-Publishes-Positive-Aviptadil-Data-in-High-Comorbidity-Critical-COVID-19-Patients-w-Respiratory-Failure

FAQ

What were the trial results for aviptadil reported by Relief Therapeutics on October 15, 2021?

The trial showed a 60-day survival rate of 81% for patients treated with aviptadil, compared to 21% for those receiving standard care.

How does aviptadil compare to standard treatment for COVID-19 according to the recent press release?

Aviptadil showed a significantly higher survival rate and recovery probability compared to standard treatment.

What is the significance of the publication in the Journal of Infectious Diseases and Treatment regarding aviptadil?

The publication confirms the positive trial results for aviptadil, supporting its development as a treatment for critical COVID-19 patients.

What is the stock symbol for Relief Therapeutics?

The stock symbol for Relief Therapeutics is RLFTF.